Advertisement

Topics

Analysis shows Victoza reduces risk of major cardiovascular events in diabetic patients

11:44 EDT 30 Aug 2017 | EPM Magazine

An analysis of the LEADER trial, evaluating the long-term effects of Victoza (liraglutide), has shown that the treatment reduces the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk.

Original Article: Analysis shows Victoza reduces risk of major cardiovascular events in diabetic patients

NEXT ARTICLE

More From BioPortfolio on "Analysis shows Victoza reduces risk of major cardiovascular events in diabetic patients"

Quick Search
Advertisement